Vivani Medical gets Australian approval to start first-in-human GLP-1 implant trial LIBERATE-1

Vivani Medical, Inc.

Approval from Bellberry HREC and TGA acknowledgement for LIBERATE-1 trial in obese/overweight subjects.
Trial will evaluate safety, tolerability, and PK of exenatide NanoPortal implant in 24 participants.
Preclinical data suggests comparable efficacy to semaglutide with twice-yearly dosing.
Enrollment expected Q4 2024; data projected in 2025; Australian R&D incentives may defray costs.
Data intended to support regulatory submissions in the US and other geographies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.